Our company was founded on a seminal invention by MIT professor Brad Pentelute (our scientific founder), that enables on-demand protein synthesis. This technology empowers us to build protein therapeutics with unlimited non-natural chemical modifications. These modifications can provide unique and enhanced functionalities--like hyperstability, bioavailability, membrane penetration and reduced immunogenicity--that are critical for next-generation therapeutic development.

Amide Technologies is an early stage biotherapeutics company that is developing a new modality of therapeutics to relieve patient suffering and modify the disease course of autoimmune diseases, inflammatory disorders, cancers and COVID19

 

 As the experts in this new and exciting field, we will bring the next series of innovations to the protein therapeutic market to improve patient outcomes and quality of life.